Cirio advises Scandinavian Real Heart in connection with its list change to Nasdaq First North Growth Market

Cirio acted as legal advisor to Scandinavian Real Heart AB (publ) in connection with its list change to Nasdaq First North Growth Market. First day of trading on Nasdaq First North Growth Market was 17 December 2021.

Scandinavian Real Heart develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Scandinavian Real Heart’s TAH has a unique, patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two chambers) which provides the opportunity to generate a physiologically adapted blood flow that mimics the body’s natural circulation. A unique concept in the medical technology world.

Cirio’s team was headed by Maria Arnoldsson (Capital Markets and Public M&A) and Per Hedman (Life Science and M&A) together with Jesper M Johansson (Capital Markets and Public M&A) and Sofie Bodlund (Life Science).

For more information, please contact: